262 related articles for article (PubMed ID: 36504883)
21. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma.
Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B
Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235
[TBL] [Abstract][Full Text] [Related]
23. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
24. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis.
Yin C; Gao M; Wang Q; Li H
Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319
[TBL] [Abstract][Full Text] [Related]
25. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z
Front Genet; 2022; 13():947551. PubMed ID: 35938003
[No Abstract] [Full Text] [Related]
26. Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma.
Xu QS; Shen ZZ; Yuan LQ
Front Cell Dev Biol; 2022; 10():968590. PubMed ID: 36467424
[TBL] [Abstract][Full Text] [Related]
27. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
28. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
29. A Prognostic Cuproptosis-Related LncRNA Signature for Colon Adenocarcinoma.
Zhong L; Zhu J; Shu Q; Xu G; He C; Fang L
J Oncol; 2023; 2023():5925935. PubMed ID: 36844874
[TBL] [Abstract][Full Text] [Related]
30. A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer.
Feng A; He L; Chen T; Xu M
Front Oncol; 2022; 12():957966. PubMed ID: 36106123
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer.
Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y
Front Genet; 2022; 13():984743. PubMed ID: 36467996
[No Abstract] [Full Text] [Related]
32. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
Front Genet; 2023; 14():1039813. PubMed ID: 36755568
[TBL] [Abstract][Full Text] [Related]
33. A signature of cuproptosis-related lncRNAs predicts prognosis and provides basis for future anti-tumor drug development in breast cancer.
Yu H; Liu Y; Zhang W; Peng Z; Yu X; Jin F
Transl Cancer Res; 2023 Jun; 12(6):1392-1410. PubMed ID: 37434691
[TBL] [Abstract][Full Text] [Related]
34. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
[TBL] [Abstract][Full Text] [Related]
35. A novel prognostic signature based on cuproptosis-related lncRNA mining in colorectal cancer.
Hou D; Tan JN; Zhou SN; Yang X; Zhang ZH; Zhong GY; Zhong L; Yang B; Han FH
Front Genet; 2022; 13():969845. PubMed ID: 36105091
[No Abstract] [Full Text] [Related]
36. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
37. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis-related lncRNAs forecast the prognosis of acute myeloid leukemia.
Zhang T; Liao D; Hu Y
Transl Cancer Res; 2023 May; 12(5):1175-1195. PubMed ID: 37304546
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of a novel cuproptosis-related lncRNA signature for predicting colorectal cancer patients' survival.
Liu F; Wu X
J Gastrointest Oncol; 2023 Apr; 14(2):650-662. PubMed ID: 37201038
[TBL] [Abstract][Full Text] [Related]
40. Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma.
Sun Q; Qin X; Zhao J; Gao T; Xu Y; Chen G; Bai G; Guo Z; Liu J
Apoptosis; 2023 Feb; 28(1-2):247-262. PubMed ID: 36344660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
